Neurocrine Biosciences' involvement in the development of a gene therapy for Parkinson's disease and other GBA1-mediated diseases through its partnership with Voyager Therapeutics could be seen as a strategic expansion of its neurological disorder treatment pipeline. This could positively influence investor perception and stock price, as it demonstrates the company's proactive approach in addressing significant unmet medical needs.

The selection of a lead development candidate in a gene therapy program is a critical milestone in drug development, indicating positive preliminary data and a clear path forward towards clinical trials. For Voyager Therapeutics, this progress in a high-impact area like Parkinson's disease treatment could attract investor interest, potentially driving up the stock price in the short term.